Featured Publications
Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.Peer-Reviewed Original ResearchExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original Research
2022
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administration
2021
Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation
Johnson JE, McGuone D, Xu ML, Jane-Wit D, Mitchell RN, Libby P, Pober JS. Coronavirus Disease 2019 (COVID-19) Coronary Vascular Thrombosis Correlation with Neutrophil but Not Endothelial Activation. American Journal Of Pathology 2021, 192: 112-120. PMID: 34599881, PMCID: PMC8479934, DOI: 10.1016/j.ajpath.2021.09.004.Peer-Reviewed Original ResearchConceptsVascular cell adhesion molecule-1Intracellular adhesion molecule-1Adhesion molecule-1Von Willebrand factorEndothelial activationMolecule-1Severe coronavirus disease 2019Neutrophil extracellular trap formationCell adhesion molecule-1COVID-19 cohortCOVID-19 patientsNeutrophil-platelet aggregatesCoronavirus disease 2019Extracellular trap formationCOVID-19Transcription factor p65Extensive thrombosisLymphocytic infiltrationMyocardial injuryThrombotic diathesisInflammatory activationNeutrophil activationCardiovascular diseaseDisease 2019Autopsy tissueSecondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients
Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overFemaleHodgkin DiseaseHumansMaleMiddle AgedRetrospective StudiesSkin NeoplasmsConceptsClassic Hodgkin lymphomaSecondary skin involvementHodgkin's lymphomaCutaneous involvementSkin involvementComprehensive histopathologic evaluationStage IV diseaseNodular sclerosis typeLarge case seriesBoard-certified dermatopathologistClassic HLSkin disseminationMixed cellularityMost patientsCase seriesSclerosis typeImmunophenotypic featuresInfiltrative plaquesFirst diagnosisHistopathologic evaluationMultiple lesionsSkin lesionsSingle lesionLarge seriesClinical diagnosis
2020
Cutaneous Involvement in Plasma Cell Myeloma
Panse G, Subtil A, McNiff JM, Glusac EJ, Ko CJ, Galan A, Myung P, Xu ML. Cutaneous Involvement in Plasma Cell Myeloma. American Journal Of Clinical Pathology 2020, 155: 106-116. PMID: 32885235, DOI: 10.1093/ajcp/aqaa122.Peer-Reviewed Original ResearchConceptsPlasma cell myelomaCutaneous involvementSquamous cell carcinomaAmyloid depositionCell carcinomaCell myelomaCases of PCMBone marrow involvementCyclin D1 immunoreactivityDisease-related deathLight chain restrictionCCND1 gene rearrangementMarrow involvementSkin involvementClinicopathologic featuresCytomorphologic spectrumCutaneous lesionsPoor outcomeCommon immunophenotypeChain restrictionClinical dataCytogenetic findingsOlder individualsGene rearrangementsMyelomaGlucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy
Nair S, Bar N, Xu ML, Dhodapkar M, Mistry PK. Glucosylsphingosine but not Saposin C, is the target antigen in Gaucher disease-associated gammopathy. Molecular Genetics And Metabolism 2020, 129: 286-291. PMID: 32044242, PMCID: PMC8223251, DOI: 10.1016/j.ymgme.2020.01.009.Peer-Reviewed Original ResearchConceptsGaucher disease type 1Monoclonal gammopathyAntigenic targetsClonal immunoglobulinDisease type 1B cell activationAccumulation of glucosylceramideGD1 patientsImmunogenic lipidsMetabolic inflammationMultiple myelomaGD patientsHigh riskTarget antigenCell activationImmunoglobulin typeGammopathyType 1PatientsGenetic deficiencyAge-related phenotypesSaposin CClonal IgLysosomal glucocerebrosidaseGlcSph
2019
Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma
Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Human Pathology 2019, 93: 54-64. PMID: 31425695, PMCID: PMC7038910, DOI: 10.1016/j.humpath.2019.08.008.Peer-Reviewed Original ResearchConceptsMantle cell lymphomaCell lymphomaAnn Arbor stage IIINovel independent prognostic factorAggressive B-cell lymphomasHigh Bim expressionAverage patient ageBim expressionIndependent prognostic factorLarge academic medical centerKi-67 indexNovel prognostic markerB-cell lymphomaAcademic medical centerCyclin D1 overexpressionHuman mantle cell lymphomaMCL cohortMIPI scoreProgressive diseaseComplete responseOverall survivalPatient agePrognostic factorsTumor cell survivalFemale ratioPhiladelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia
Gong Z, Xu ML, Chen M, Cui W, Kantarjian HM, Cortes JE, Zhou T, Tang G, Wang W, Medeiros LJ, Hu S. Philadelphia chromosome‐negative acute leukemia in patients with chronic myeloid leukemia. American Journal Of Hematology 2019, 94: e256-e259. PMID: 31273842, DOI: 10.1002/ajh.25571.Peer-Reviewed Original ResearchAbnormal KaryotypeAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBlast CrisisBone MarrowChromosome AberrationsDiagnosis, DifferentialDiagnostic ErrorsFemaleFollow-Up StudiesHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesNeoplasms, Second PrimaryPhiladelphia ChromosomeRetrospective StudiesYoung AdultClinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Chen PH, Yang Y, O'Malley DP, Xu ML. Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx. Annals Of Diagnostic Pathology 2019, 41: 129-135. PMID: 31247533, DOI: 10.1016/j.anndiagpath.2019.06.007.Peer-Reviewed Original ResearchConceptsB-cell non-Hodgkin lymphomaEBV-negative casesAggressive B-NHLPD-L1Peptide receptor radionuclide therapyAggressive B-cell lymphomasEBV-positive DLBCLEBV-positive patientsDisease-free intervalPrimary clinical outcomeYear of diagnosisEBV-positive casesReceptor radionuclide therapyExpression of SSTR2Non-Hodgkin lymphomaExpression of CD30Five yearsAvailable outcome dataB-cell lymphomaEBV negativityInitial therapyClinicopathologic characteristicsBetter prognosisCase seriesClinical outcomesMantle Cell Lymphoma With Mantle Zone Growth Pattern
Yuan J, Li S, Liu X, Su RJ, Chen M, Wu X, Zheng G, Smith LM, Wang L, Li Y, Liu C, Zhou J, Shen Q, Zhang L, Wang E, Xu ML, Pan Z. Mantle Cell Lymphoma With Mantle Zone Growth Pattern. American Journal Of Clinical Pathology 2019, 152: 132-145. PMID: 31140550, DOI: 10.1093/ajcp/aqz043.Peer-Reviewed Original ResearchConceptsMantle zone growth patternMantle cell lymphomaCell lymphomaHigher clinical stageOverall survivalPathologic featuresClinicopathologic dataClinical stageSuspicious morphologyClinical significanceCyclin D1Lymphoma cellsCell cytologyGrowth patternSignificant differencesPatientsLymphomaChemotherapyLymphCD5ImmunostainsCytologyCasesClinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms
Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances 2019, 3: 1540-1545. PMID: 31085507, PMCID: PMC6517660, DOI: 10.1182/bloodadvances.2019000090.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AFemaleHumansMaleMiddle AgedMutationMyelodysplastic SyndromesNuclear ProteinsNucleophosminPrognosisProportional Hazards ModelsProtein Tyrosine Phosphatase, Non-Receptor Type 11Survival RateTumor Suppressor Protein p53ConceptsMyelodysplastic syndromeMyeloid neoplasmsDe novo acute myeloid leukemia (AML) patientsNovo acute myeloid leukemia patientsAcute myeloid leukemia patientsBone marrow blastsAggressive clinical courseStem cell transplantLimited case seriesShorter overall survivalMyeloid leukemia patientsIntensive therapeutic regimensTotal mutation countsMarrow blastsOverall survivalClinical courseCase seriesCell transplantMultivariable analysisTherapeutic regimensLeukemia patientsLarge cohortYounger agePatientsNormal karyotype
2018
Small Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis
Rahmani M, Halene S, Xu ML. Small Cell Variant of Intravascular Large B‐Cell Lymphoma: Highlighting a Potentially Fatal and Easily Missed Diagnosis. BioMed Research International 2018, 2018: 9413015. PMID: 29850589, PMCID: PMC5903319, DOI: 10.1155/2018/9413015.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAdultAgedAged, 80 and overBiopsyDemographyFemaleFollow-Up StudiesHumansLiverLymphoma, Large B-Cell, DiffuseMaleMiddle AgedConceptsIntravascular large B-cell lymphomaB-cell lymphomaLarge B-cell lymphomaSmall cell morphologySmall cell variantCases of IVLBCLCell variantHodgkin's B-cell lymphomaRandom skin biopsySmall bowel biopsyHigh clinical suspicionLarge atypical cellsSmall cell lymphomaSmall blood vesselsBowel biopsyClinical suspicionLymph nodesRetrospective reviewClinicopathologic featuresSmall bowelPoor prognosisAtypical cellsFallopian tubeSkin biopsiesDifferential diagnosis
2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia
Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAged, 80 and overAntibodies, BispecificAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowBreast NeoplasmsCarcinoma, Transitional CellCytarabineFemaleHumansLymphoma, B-CellMercaptopurineMethotrexateNeoplasms, Second PrimaryPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSalvage TherapyUrinary Bladder NeoplasmsVincristine
2015
Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary
Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma–is it necessary. Oncotarget 2015, 6: 13933-13945. PMID: 26101854, PMCID: PMC4546442, DOI: 10.18632/oncotarget.4324.Peer-Reviewed Original ResearchConceptsEpstein-Barr virus-positive diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaYears of ageFrequent expressionOlder patientsAge cutoffMonoclonal B-cell proliferationArbitrary age cutoffsPoor performance statusGenetic featuresMore frequent expressionB cell proliferationPerformance statusYounger patientsClinicopathologic evidencePatient groupDLBCL patientsTreatment outcomesPatientsDLBCLGene expression profilingCD30Lymphoma
2014
Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract. International Journal Of Gynecological Cancer 2014, 24: 1250-1255. PMID: 25010039, PMCID: PMC8139417, DOI: 10.1097/igc.0000000000000201.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDiagnosis, DifferentialDoxorubicinFemaleGenital Neoplasms, FemaleGynecologic Surgical ProceduresHumansLymphoma, Non-HodgkinMiddle AgedPrednisolonePrednisonePregnancyPregnancy Complications, NeoplasticRetrospective StudiesSurvival AnalysisTeniposideVincristineYoung AdultConceptsNon-Hodgkin lymphomaFemale genital tractGenital tractGynecologic malignanciesPara-aortic lymph nodesPrimary non-Hodgkin lymphomaDiffuse large B-cell lymphomaYale-New Haven HospitalLarge B-cell lymphomaConcomitant radiation therapyRadical gynecologic surgeryCommon histologic typeOverall median survivalSingle institution experienceStem cell transplantationRare gynecologic malignancyDiagnosis of lymphomaAnn Arbor systemB-cell lymphomaWorld Health OrganizationMedian survivalRecurrent diseaseCombination chemotherapyMedian ageUterine corpusMarrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability
Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow Assessment for Hemophagocytic Lymphohistiocytosis Demonstrates Poor Correlation With Disease Probability. American Journal Of Clinical Pathology 2014, 141: 62-71. PMID: 24343738, DOI: 10.1309/ajcpmd5tjefoovbw.Peer-Reviewed Original ResearchConceptsFindings of hemophagocytosisHemophagocytic lymphohistiocytosisHistologic findingsProbability of HLHSecondary hemophagocytic lymphohistiocytosisCore biopsy specimenCore biopsy specimensDisease probabilityFisher's exact testElevated ferritinClinical suspicionMarrow assessmentHLH groupBiopsy specimenLaboratory criteriaBiopsy specimensMedical recordsHemophagocytosisExact testLymphohistiocytosisPatientsSignificant correlationAspiratesPoor correlationFindings
2009
HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study
Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P. HER‐2/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 2009, 56: 269-273. PMID: 20102407, DOI: 10.1111/j.1365-2559.2009.03464.x.Peer-Reviewed Original Research